1. Clinical & Scientific Overview
Cefixime Trihydrate (TIP-MED-000132, Reference Code [8.4]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Third-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Bactericidal; WHO 'Watch' Group).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory 3-Year Red-Border Register Retention) • NLEM 2022.
Taxim-O (Alkem), Zifi (FDC), Mahacef (Mankind)
Oral Film-Coated / Dispersible Tablets: 100 mg, 200 mg, 400 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
3. Mechanism of Action & Pharmacodynamics
Binds with high affinity to bacterial Penicillin-Binding Proteins (predominantly PBP3 and PBP1a/1b) in Gram-negative Enterobacterales and streptococci, acylating the transpeptidase active site, inhibiting peptidoglycan cross-linking, and inducing filamentous cell elongation followed by bactericidal osmotic lysis. Stable against many plasmid-mediated TEM-1/SHV-1 beta-lactamases (hydrolysed by ESBL and AmpC).
4. Therapeutic Indications & Evidence-Supported Uses
- Uncomplicated enteric fever (Salmonella Typhi / Paratyphi) and oral step-down after IV Ceftriaxone
- Acute uncomplicated urinary tract infections, pyelonephritis step-down, and acute otitis media / bacterial pharyngitis
- Uncomplicated gonococcal urethritis/cervicitis (when Ceftriaxone IM is unavailable)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults: 200 mg orally every 12 hours or 400 mg once daily. Enteric Fever: 20 mg/kg/day (up to 400 mg twice daily) for 10–14 days.
Administration & Meal Timing: Oral; with or without food (taking with food reduces GI upset without lowering overall absorption).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
No adjustment required.
Reduce dose to 75% (300 mg/day) when CrCl is 21–60 mL/min, and to 50% (200 mg once daily) when CrCl < 20 mL/min or on haemodialysis.
No adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Immediate IgE-mediated anaphylaxis or severe cutaneous adverse reaction (SJS/TEN) to any Cephalosporin or Penicillin
Key Clinical Precautions: No adjustment required.
8. Adverse Effects Profile
- Diarrhoea and loose stools (10%–15%), abdominal pain, dyspepsia
- Hypersensitivity reactions (maculopapular rash, urticaria, rare anaphylaxis)
- Clostridioides difficile-associated diarrhoea (CDAD)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Warfarin: Cephalosporins reduce vitamin K-producing gut flora and may increase INR
- Carbamazepine: Cefixime may elevate Carbamazepine plasma concentrations
- Live Oral Typhoid Vaccine (Ty21a): delay vaccine by >=72 hours after stopping antibiotic
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- GOVERNANCE NOTE: Cefixime is a Schedule H1 antibiotic under the Drugs Rules 1945 — dispense only against a valid registered medical practitioner's prescription and log in the Schedule H1 register.
- For paediatric dry syrup, reconstitute with boiled and cooled water up to the ring mark, shake well before each dose, and discard unused suspension after 7–14 days.
- Complete the full course even if fever subsides after 3–4 days.
Storage, Stability & Dispensing Safeguards: Store tablets below 25–30°C; keep reconstituted oral suspension below 25°C and use within 7–14 days.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.19] Meropenem, Ertapenem & Imipenem + Cilastatin (Reserve Carbapenems) — Broad-Spectrum Parenteral Carbapenem Beta-Lactam Antibiotics — IC
- [8.20] Clarithromycin & Erythromycin — Macrolide 50S Ribosomal Protein Synthesis Inhibitors — Potent CYP
- [8.21] Clindamycin Hydrochloride / Phosphate — Lincosamide 50S Ribosomal Inhibitor & Bacterial Toxin Suppressor
- [8.22] Linezolid — Oxazolidinone 50S Ribosomal Initiation Complex Inhibitor — ICMR '